BriaCell Therapeutics Corp. (TSE:BCT – Free Report) – Equities researchers at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of BriaCell Therapeutics in a research report issued to clients and investors on Thursday, September 19th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($1.09) per share for the year, up from their prior forecast of ($1.90). HC Wainwright also issued estimates for BriaCell Therapeutics’ Q4 2024 earnings at ($0.71) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at ($0.33) EPS, FY2027 earnings at ($0.26) EPS and FY2028 earnings at ($0.16) EPS.
BriaCell Therapeutics Price Performance
BCT opened at C$0.87 on Monday. BriaCell Therapeutics has a one year low of C$0.64 and a one year high of C$8.65. The firm has a market capitalization of C$26.72 million, a price-to-earnings ratio of -1.74 and a beta of 1.74. The business has a 50 day simple moving average of C$0.93 and a two-hundred day simple moving average of C$2.00.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
Read More
- Five stocks we like better than BriaCell Therapeutics
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Election Stocks: How Elections Affect the Stock Market
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Stock Average Calculator
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.